The company's recent INFINITY launch is "moving into high gear," according to the company President and CEO Robert Palmisano, and combined with executing the Vital Few initatives, he expects further strength and expansion in the company's competitive position in the market. 5. Mr. Palmisano also feels the merger with Tornier could be huge for the company. "We believe that our pending merger with Tornier will enhance shareholder value through the creation of the premier high-growth extremities-biologics company that is uniquely positioned with leading technologies and specialized sales force in three of the fastest-growing areas of orthopedics," he said. 6. The company is banking on the Augment Bone Graft launch to additional depth to the company's extrmities and biologics product portfolio and providing a platform technology for future new product development. 7.